Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is current
Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc
Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its
Takeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer therapies for $525 million, as research into the technology gathers pace.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.